Form DEF 14A KORU Medical Systems For: 9 April

KORU Medical Systems, Inc., a medical technology company specializing in subcutaneous drug delivery systems, filed its definitive proxy statement (Form DEF 14A) with the U.S. Securities and Exchange Commission (SEC) on April 9, 2025, to provide shareholders with detailed information ahead of its upcoming annual meeting. This mandatory regulatory filing outlines the matters to be voted on and discloses critical corporate governance information, allowing investors to make informed decisions regarding the company's leadership and strategic direction. The DEF 14A filing typically includes the agenda for the annual shareholder meeting, such as the election of directors to the company's board, executive compensation plans (say-on-pay votes), and the ratification of the appointed independent auditor. For a company like KORU Medical Systems, which focuses on innovative infusion systems like the FreedomEdge® syringe pump, these governance documents are closely scrutinized by investors interested in the company's management stability and its strategy for growth in the competitive medical device market. Proxy statements serve as a primary communication tool between a public company's management and its shareholders. The filing of this document indicates that KORU Medical Systems is proceeding with its corporate calendar and adhering to SEC regulations for publicly traded companies. The information contained within helps set the stage for the annual meeting, where shareholders exercise their voting rights on issues central to the company's oversight and future.